
Opinion|Videos|May 23, 2025
Important Patient and Clinical Considerations When Choosing Therapy in RRMM Following CAR T Therapy
Author(s)Aimaz Afrough, MD, Natalia Neparidze, MD
Panelists discuss how selinexor offers convenient oral administration, bispecific antibodies provide high response rates but may present toxicity risks, and cytotoxic chemotherapy is effective for aggressive disease but carries significant adverse effects and risks.
Advertisement
Episodes in this series

Physician Summary: Advantages and Disadvantages of Available Treatment Options
Selinexor:
- Advantages:
- Oral administration allows for easier access and reduces the need for frequent clinic visits.
- Convenient for patients who may prefer oral therapy over intravenous options.
- Disadvantages:
- Can have adverse effects like nausea and fatigue.
- May require dose adjustments based on tolerance.
Bispecific Antibodies:
- Advantages:
- High response rates in patients, offering effective disease control.
- Available as off-the-shelf therapies, providing rapid access.
- Disadvantages:
- Potential for toxicity, including cytokine release syndrome and neurotoxicity.
- Access limitations due to the need for specialized administration and possible cost issues.
- Infection risk due to immune modulation.
Cytotoxic Chemotherapy:
- Advantages:
- Effective for aggressive disease with quick action in cytoreduction.
- Broad applicability in various clinical settings.
- Disadvantages:
- Associated with myelosuppression, renal dysfunction, and the potential for hospitalization due to adverse effects.
- T-cell suppression, which can impair responses to subsequent immunotherapies.
Key Takeaway: Each treatment has its own benefit-risk profile—selinexor offers convenience, bispecific antibodies deliver high response rates, and cytotoxic chemotherapy can be effective in aggressive disease, though each carries specific challenges in terms of toxicity and patient burden.
Advertisement
Related to this article

An exploratory analysis of the phase 3 KEYNOTE-B15 trial found that ctDNA status was strongly prognostic for event-free survival regardless of treatment arm.

The KEYNOTE-866 trial did not meet its EFS primary end point with perioperative pembrolizumab added to neoadjuvant cisplatin and gemcitabine.

The sacituzumab govitecan, enfortumab vedotin, and zimberelimab triplet produced early, durable responses in untreated metastatic urothelial cancer.

Surufatinib plus serplulimab and cisplatin/etoposide produced a 69.8% ORR in advanced extrapulmonary neuroendocrine carcinoma.

Efficacy outcomes in KEYNOTE-905 were consistent with a contribution of both enfortumab vedotin and pembrolizumab in cisplatin-ineligible MIBC.

Patient-reported outcomes from the phase 3 lidERA trial show preserved functioning and less frequent joint pain with giredestrant vs standard endocrine therapy.

Arcotatug tavatecan improved PFS and OS vs physician’s choice in previously treated, CLDN18.2-positive advanced gastric and GEJ cancer.
Advertisement
Advertisement
Trending on OncLive
1
Polls Reveal Top Picks for Lung Cancer Abstracts of Interest at ESMO 2026
2
Poll Results Highlight Gynecologic Cancer Abstracts of Interest at ESMO 2026
3
Adjuvant Giredestrant Preserves QOL With Sustained Tolerability in ER+, HER2– Early Breast Cancer
4
Arcotatug Tavatecan Improves Survival in CLDN18.2+ Advanced Gastric or GEJ Adenocarcinoma
5

